SubHero Banner

Oral JAK Inhibitors (Xeljanz®/XR, Olumiant®, Rinvoq®) – Safety update

September 1, 2021 - The FDA announced that after review of a large randomized safety clinical trial, there is an increased risk of serious heart-related events such as heart attack or stroke, cancer, blood clots, and death with Xeljanz, Xeljanz XR (tofacitinib). The FDA believes the other Janus kinase (JAK) inhibitors, Olumiant (baricitinib) and Rinvoq (upadacitinib), have similar risks because they share the same mechanism of action as Xeljanz.

Download PDF